Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
RESEARCH TOOLSreports
Holding TSE:EPRX?
Track your performance easily
EPRX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$3.07 - C$7.64
Previous CloseC$4.4
Volume10.01K
Average Volume (3M)27.83K
Market Cap
C$159.58M
Enterprise ValueC$139.43M
Total Cash (Recent Filing)C$23.32M
Total Debt (Recent Filing)C$4.66M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Apr 01, 2025EPS Estimate
-C$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding35,622,553
10 Day Avg. Volume81,840
30 Day Avg. Volume27,829
Standard Deviation0.22
R-Squared0.04
Alpha0.00201
Financial Highlights & Ratios
Price to Book (P/B)10.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eupraxia Pharmaceuticals News
PremiumCompany Announcements
Eupraxia Pharmaceuticals Reports Q3 Progress and Funding
PremiumCompany Announcements
Eupraxia Pharmaceuticals Secures C$44.5 Million Investment
PremiumCompany Announcements
Eupraxia Pharmaceuticals Showcases Innovations in Drug DeliveryPremiumCompany Announcements
Eupraxia’s EP-104IAR Gains Attention in Rheumatology
PremiumCompany Announcements
Eupraxia Pharmaceuticals Highlights Innovation at UEG Week 2024
PremiumCompany Announcements
Eupraxia Pharmaceuticals Enhances Leadership Team
Options Prices
Currently, No data available
---
Ownership Overview
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$3.07 and its highest was C$7.64 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Currently, no data Available
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 142 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -C$0.168 earnings per share for the quarter, beating the consensus estimate of -C$0.177 by C$0.009.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Overvalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -C$0.15.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 35,622,555 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.168 in its last earnings report, beating expectations of -C$0.177. Following the earnings report the stock price went down -0.227%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
---
Eupraxia Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth C$7.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-59.24%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
---
EPRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering EPRX
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-33.67%
reiterated a buy rating 8 months ago
Copying Rahul Sarugaser's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -33.67% per trade.
---